Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Section of Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
J Neurooncol. 2021 Oct;155(1):93-100. doi: 10.1007/s11060-021-03847-y. Epub 2021 Oct 1.
Endocrine deficiencies are common following Craniospinal irradiation (CSI) in children with brain tumors, but empirical data comparing outcomes following proton (PRT) and photon radiation therapy (XRT) are limited.
This retrospective chart review compared the incidence of hypothyroidism, Growth hormone deficiency (GHD), and Adrenal insufficiency (AI) in patients with medulloblastoma treated with XRT and PRT between 1997 and 2016. All patients received CSI and had routine endocrine screening labs to evaluate for thyroid dysfunction, GHD, and AI. We used proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals (CI) comparing the development of hypothyroidism, AI, and GHD between radiation modalities, adjusting for age at diagnosis, sex, race/ethnicity, and CSI dose.
We identified 118 patients with medulloblastoma who were followed for a median of 5.6 years from the end of radiotherapy. Thirty-five (31%) patients developed hypothyroidism, 71 (66%) GHD, and 20 (18%) AI. Compared to PRT, XRT was associated with a higher incidence of primary hypothyroidism (28% vs. 6%; HR = 4.61, 95% CI 1.2-17.7, p = 0.03). Central hypothyroidism, GHD, and AI incidence rates were similar between the groups.
Primary hypothyroidism occurs less often after PRT CSI, compared to XRT CSI. This suggests that the thyroid and pituitary glands receive less radiation after spine and posterior fossa boost RT, respectively, using PRT.
颅脑脊柱放疗(CSI)后儿童内分泌缺乏症较为常见,但质子(PRT)和光子放疗(XRT)治疗后结果的实证数据有限。
本回顾性图表研究比较了 1997 年至 2016 年间接受 XRT 和 PRT 治疗的髓母细胞瘤患者发生甲状腺功能减退、生长激素缺乏症(GHD)和肾上腺功能不全(AI)的发病率。所有患者均接受 CSI,并进行常规内分泌筛查实验室检查,以评估甲状腺功能障碍、GHD 和 AI。我们使用比例风险回归来计算风险比(HR)和 95%置信区间(CI),以比较两种放射治疗方式发生甲状腺功能减退、AI 和 GHD 的风险,调整诊断时的年龄、性别、种族/族裔和 CSI 剂量。
我们确定了 118 例髓母细胞瘤患者,从放疗结束到随访中位时间为 5.6 年。35 例(31%)患者发生甲状腺功能减退,71 例(66%)患者发生 GHD,20 例(18%)患者发生 AI。与 PRT 相比,XRT 更易导致原发性甲状腺功能减退(28% vs. 6%;HR=4.61,95%CI 1.2-17.7,p=0.03)。两组中枢性甲状腺功能减退、GHD 和 AI 的发生率相似。
与 XRT CSI 相比,PRT CSI 后原发性甲状腺功能减退症的发生率较低。这表明在分别使用 PRT 进行脊柱和后颅窝加量放疗时,甲状腺和垂体接收到的放射剂量更少。